JamesMWellsMDMSPH

Pulmonology • Birmingham, AL

Asthma & COPD, Critical Care Medicine, Pleural Disease

Associate Professor

Join to view full profile

Dr. Wells is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wells' full profile

Already have an account?

Office
700 19th St S
Birmingham, AL 35233
Phone+1 205-933-8101

Fax+1 205-933-4497
Is this information wrong?

Summary

Dr. James Wells is a pulmonologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital and Birmingham VA Medical Center. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 14 years. He specializes in asthma & copd, critical care medicine, and pleural disease and is experienced in chronic obstructive pulmonary disease and chronic bronchitis. He has more than 100 publications and over 500 citings.

Education & Training

University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2009 - 2012
University of Alabama HospitalResidency, Internal Medicine, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005

Certifications & Licensure

AL State Medical License 2007 - 2024
SC State Medical License 2017 - 2019
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2007 Nov 01
Active, not recruiting
Study of COPD Subgroups and Biomarkers Start of enrollment: 2010 Nov 01
Active, not recruiting
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Start of enrollment: 2018 Oct 29
Completed
Phase 2
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency Start of enrollment: 2019 Apr 08
Completed
Phase 2
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype Start of enrollment: 2020 Jul 24
Completed
Phase 2
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Start of enrollment: 2020 Sep 04
Completed
Phase 2
COVID-19 Study of Safety and Tolerability of Alvelestat Start of enrollment: 2021 Jan 25
Completed
Phase 1, Phase 2
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) Start of enrollment: 2021 Jan 29
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

127 citations
CT Scan-Measured Pulmonary Artery to Aorta Ratio and Echocardiography for Detecting Pulmonary Hypertension in Severe COPD
Anand S Iyer, J. Michael Wells, Sonia Vishin, Surya P. Bhatt, Keith M. Wille
Chest. 2014-04-01
332 citations
Pulmonary arterial enlargement and acute exacerbations of COPD.
J. Michael Wells, George R. Washko, MeiLan K. Han, Naseer Abbas, Hrudaya Nath
The New England Journal of Medicine. 2012-09-06
87 citations
Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years
Surya P. Bhatt, Young-il Kim, Kathy Harrington, John E. Hokanson, Sharon M. Lutz
Thorax. 2018-01-11

Hospital Affiliations

University of Alabama HospitalBirmingham, Alabama
Birmingham VA Medical CenterBirmingham, Alabama